Skip to main content
Year archive

Spexis AG — 2023 filings

All 38 regulatory filings released by Spexis AG (SPEX) in 2023, sourced directly from the official regulator.

38 Filings
2023 Period
2023 filings (38)
Filing Released Lang
Spexis is Granted Debt-Restructuring Moratorium
Legal Proceedings Report
2023-12-05 English
Spexis is Granted Debt-Restructuring Moratorium
Legal Proceedings Report
2023-12-05 English
Spexis Provides Update Regarding Debt-Restructuring Moratorium
Capital/Financing Update
2023-11-29 English
Spexis Provides Update Regarding Debt-Restructuring Moratorium
Legal Proceedings Report
2023-11-29 English
Spexis to file an application for a debt-restructuring moratorium
Legal Proceedings Report
2023-11-08 English
Spexis to file an application for a debt-restructuring moratorium
Capital/Financing Update
2023-11-08 English
Spexis Announces Changes to the Executive Committee
Board/Management Information
2023-11-01 English
Spexis Announces Changes to the Executive Committee
Board/Management Information
2023-11-01 English
Spexis gibt Änderungen in der Geschäftsleitung bekannt
Board/Management Information
2023-11-01 German
Spexis to host business update conference call on October 9, 2023
Regulatory Filings
2023-10-06 English
Spexis to host business update conference call on October 9, 2023
Report Publication Announcement
2023-10-06 English
Spexis provides business update and announces financial results for the first half of 2023
Earnings Release H1 2023
2023-09-29 English
Spexis provides business update and announces financial results for the first half of 2023
Earnings Release H1 2023
2023-09-29 English
Spexis announces the appointment of Goncalo Bernardes, Ph.D., as acting Head of Chemical Biology
Board/Management Information
2023-09-28 English
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
Board/Management Information
2023-09-28 English
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin studies
Capital/Financing Update
2023-08-15 English
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies
Capital/Financing Update
2023-08-15 English
Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions
M&A Activity
2023-06-30 English
Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions
M&A Activity
2023-06-30 English
Spexis announces the results of its Annual General Meeting 2023
AGM Information
2023-06-26 English
Spexis announces the results of its Annual General Meeting 2023
AGM Information
2023-06-26 English
Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances
Regulatory Filings
2023-06-07 English
Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances
Regulatory Filings
2023-06-07 English
Spexis provides business update and announces financial results for the full year 2022
Earnings Release FY 2022
2023-05-30 English
Spexis provides business update and announces financial results for the full year 2022
Earnings Release FY 2022
2023-05-30 English
Spexis informiert über die aktuelle Geschäftsentwicklung und gibt Finanzergebnis für das Geschäftsjahr 2022 bekannt
Earnings Release FY 2022
2023-05-30 German
Spexis has received temporary approval of an extension until 31 of May 2023 for the disclosure obligation in connection with the publication and the filing of the annual report 2022.
Report Publication Announcement
2023-04-28 English
Spexis has received temporary approval of an extension until 31 of May 2023 for the disclosure obligation in connection with the publication and the filing of the annual report 2022.
Report Publication Announcement
2023-04-28 English
Spexis erhält vorläufige Genehmigung für eine Ausnahme bzw. Befreiung von der Offenlegungspflicht im Zusammenhang mit der Veröffentlichung des Geschäftsberichts 2022
Report Publication Announcement
2023-04-28 German
Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin Phase 3 study
Capital/Financing Update
2023-04-18 English
Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study
Share Issue/Capital Change
2023-04-18 English
Spexis gibt den Abschluss einer Kapitalzusage in Höhe von 4,5 Mio. USD von SPRIM Global Investments (SGI) bekannt, um den Beginn der ColiFin®-Phase 3-Studie zu ermöglichen
Capital/Financing Update
2023-04-18 German
Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin
Capital/Financing Update
2023-02-08 English
Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®
Capital/Financing Update
2023-02-08 English
Spexis und SPRIM Global Investments (SGI) geben Pläne für eine Partnerschaft zur Finanzierung klinischer Studien bekannt, die bis zur Hälfte der geplanten Kosten für die klinische Entwicklung von Coli
Capital/Financing Update
2023-02-08 German
Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound
Earnings Release Q1 2023
2023-01-09 English
Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound
Regulatory Filings
2023-01-09 English
Spexis gibt gute Verträglichkeits- und Pharmakokinetik-Ergebnisse der ersten klinischen Studie am Menschen zur Inhalation des neuartigen makrozyklischen Wirkstoffs Murepavadin bekannt
Legal Proceedings Report
2023-01-09 German